Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | RRM1 | P23921 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6432150 | 1.00 | GSR (0.52) | GSRGNAI3GNAO1GNAI1DPP7 | |
| Hydrochloric Acid SCHEMBL27956742 | 0.98 | GSR (0.50) | GSRGNAI3GNAO1GNAI1DPP7 | |
| Hydrochloric Acid SCHEMBL27956744 | 0.98 | GSR (0.50) | GSRGNAI3GNAO1GNAI1DPP7 | |
| Hydrochloric Acid SCHEMBL5846878 | 0.98 | GSR (0.50) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL27869324 | 0.94 | DPP7 (0.44) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL19547634 | 0.94 | DPP7 (0.44) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL28284269 | 0.92 | GSR (0.44) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL16893986 | 0.92 | GSR (0.44) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL29233121 | 0.92 | GSR (0.44) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL2494020 | 0.91 | GNAI3 (0.51) | GSRGNAI3GNAO1GNAI1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720322-A2 | ENZYME-CATALYZED REGIOSELECTIVE POLYMERIZATION FOR PREPARATION OF LINEAR POLYLYSINE OR POLYARGININE | BASF SE (DE) | 2026-04-08 | — | — | EP | claimed |
| WO-2024245141-A9 | ENZYME-CATALYZED REGIOSELECTIVE POLYMERIZATION FOR PREPARATION OF LINEAR POLYLYSINE OR POLYARGININE | BASF SE (DE) | 2025-02-06 | — | — | WO | claimed |
| WO-2024245141-A2 | ENZYME-CATALYZED REGIOSELECTIVE POLYMERIZATION FOR PREPARATION OF LINEAR POLYLYSINE OR POLYARGININE | BASF SE (DE) | 2024-12-05 | — | — | WO | claimed |
| EP-3894064-B1 | PROCESS FOR PREPARING MICROCAPSULES | FIRMENICH & CIE (CH) | 2023-11-15 | — | — | EP | claimed |
| CN-103694467-B | Biocompatible thermosensitive N-acetyl-L-glutamic acid/lysine propyl ester and preparation method | HEBEI UNIVERSITY (CN) | 2016-01-06 | — | — | CN | claimed |
| EP-1603549-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | Yu, Ruey J., Dr. (US) | 2005-12-14 | — | — | EP | claimed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | claimed |
| WO-2004082628-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-30 | — | — | WO | claimed |
| EP-4720322-A2 | ENZYME-CATALYZED REGIOSELECTIVE POLYMERIZATION FOR PREPARATION OF LINEAR POLYLYSINE OR POLYARGININE | BASF SE (DE) | 2026-04-08 | — | — | EP | disclosed |
| CN-120040435-A | Mangiferin and derivatives thereof, preparation method and medical application thereof | 安徽中医药大学 | 2025-05-27 | — | — | CN | disclosed |
| WO-2024245141-A9 | ENZYME-CATALYZED REGIOSELECTIVE POLYMERIZATION FOR PREPARATION OF LINEAR POLYLYSINE OR POLYARGININE | BASF SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2024245141-A2 | ENZYME-CATALYZED REGIOSELECTIVE POLYMERIZATION FOR PREPARATION OF LINEAR POLYLYSINE OR POLYARGININE | BASF SE (DE) | 2024-12-05 | — | — | WO | disclosed |
| EP-4446310-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | Asahi Kasei Kabushiki Kaisha (JP) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023106377-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | 旭化成株式会社 | 2023-06-15 | — | — | WO | disclosed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | disclosed |
| WO-2004082628-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20030027733-A1 | Partial ester of cellulose with nitrogenous carboxylic acid and process for producing the same | AJINOMOTO CO., INC. (JP) | 2003-02-06 | — | — | US | disclosed |
| EP-1270598-A1 | PARTIAL ESTER OF CELLULOSE WITH NITROGENOUS CARBOXYLIC ACID AND PROCESS FOR PRODUCING THE SAME | Ajinomoto Co., Inc. (JP) | 2003-01-02 | — | — | EP | disclosed |
| WO-2000051556-A1 | HAIR CARE COMPOSITIONS COMPRISING AMINO ACID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
| EP-0326799-A2 | Enzymatic process for synthesizing peptides | Degussa Aktiengesellschaft (DE) | 1989-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027733-A1 | Partial ester of cellulose with nitrogenous carboxylic acid and process for producing the same | NRDC, FASN, Q6ZSR9 | GSR 3363/4885GNAI3 4711/4885GNAO1 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.